CERN - CERN STOCK NEWS

Oracle Corporation has successfully completed its acquisition of Cerner Corporation, with a majority of Cerner's outstanding shares validly tendered by June 6, 2022. Approximately 204,280,589 shares, or 69.2%, were tendered, satisfying the conditions for the tender offer. The acquisition is set to close on June 8, 2022. Larry Ellison, Oracle's Chairman, will discuss the strategic plans for transforming healthcare in a virtual event on June 9, 2022. This acquisition is anticipated to enhance Oracle's healthcare capabilities, although risks related to integration and market conditions remain.

Oracle Corporation has announced the extension of its all-cash tender offer for Cerner Corporation until June 6, 2022. The offer is priced at $95.00 per share. This extension aims to satisfy remaining conditions related to foreign competition and investment laws. As of May 9, 2022, approximately 29.78 million shares, representing about 10.1% of Cerner's outstanding shares, had been tendered. All other terms of the offer remain unchanged, and Oracle has indicated that further extensions may occur in compliance with SEC regulations.

Cerner Corporation (Nasdaq: CERN) reported strong earnings growth for Q1 2022, attributed to margin expansion. The results for the quarter ended March 31, 2022, showcase a significant improvement in financial performance, reflecting the company's commitment to enhancing healthcare technologies. This earnings report emphasizes Cerner's role in connecting health information systems worldwide, which is critical for better patient care and operational efficiency.

The International Gaucher Alliance and Cerner Corporation (CERN) have launched the GARDIAN registry to improve understanding and treatment of Gaucher Disease, the most common Lysosomal Storage Disorder. The registry, which opened for registrations on April 25, 2022, is aimed at collecting clinical and health outcome data from patients with neuronopathic Gaucher Disease. This initiative seeks to address significant gaps in care and support by using advanced technology through the Atom5 platform, enhancing patient-centric treatment approaches.

Oracle Corporation (NYSE: ORCL) has extended its tender offer for Cerner Corporation (Nasdaq: CERN) until May 11, 2022. The all-cash offer remains at $95.00 per share for all outstanding shares. As of April 8, 2022, approximately 33,951,780 shares, or about 11.5% of Cerner's outstanding shares, have been validly tendered. The extension allows time for satisfying merger conditions, including regulatory approvals. All other terms of the tender offer remain unchanged, and further extensions may occur as needed.

Nuance Communications and Cerner Corporation have expanded their collaboration to integrate Nuance DAX technology with Cerner Millennium EHR. This integration aims to ease clinical documentation burdens on healthcare providers, addressing clinician burnout and improving patient care. Key statistics highlight a projected shortage of 3.2 million healthcare workers by 2026 and that physicians spend over 16 minutes per patient in Cerner's system. The enhanced collaboration is expected to automate data entry, improving efficiency and provider satisfaction.

Cerner Corporation (Nasdaq: CERN) has declared a cash dividend of $0.27 per share, payable on April 19, 2022, to shareholders of record as of March 28, 2022. The Board will continue to assess future dividends based on financial performance, cash flow, and other relevant factors. Cerner specializes in healthcare technology, enhancing care management and operational efficiency across provider facilities globally.

Oracle Corporation has extended its tender offer for the acquisition of Cerner Corporation until April 13, 2022. The all-cash offer is set at $95.00 per share of Cerner's common stock. As of March 14, 2022, approximately 25,587,409 shares, or 10.1% of outstanding shares, were validly tendered. This extension allows additional time for satisfying necessary conditions under foreign competition laws. All other offer terms remain unchanged, and further extensions may occur as per regulatory rules.

Oracle Corporation (NYSE: ORCL) announced that the waiting period under the Hart-Scott-Rodino Act for its acquisition of Cerner Corporation (Nasdaq: CERN) expired on February 22, 2022. This step signifies progress in the acquisition process. The tender offer for Cerner shares is set to expire at midnight on March 16, 2022. However, Oracle anticipates an extension to allow time for remaining conditions to be satisfied. The acquisition aims to enhance Oracle's healthcare service capabilities, although it remains subject to various regulatory clearances.